Abstract
A parkinsonian syndrome can be produced in nonhuman primates by administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Parkinsonian-like symptoms induced acutely by MPTP were ameliorated after treatment with GM1 ganglioside, a substance shown to have neurotrophic effects on the damaged dopamine system in rodents. Treatment with GM1 ganglioside also increased striatal dopamine and metabolite levels and enhanced the dopaminergic innervation of the striatum as demonstrated by tyrosine hydroxylase immunohistochemistry. These results suggest that GM1 ganglioside may hold promise as a therapeutic agent for the treatment of Parkinson's disease.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
-
3,4-Dihydroxyphenylacetic Acid / metabolism
-
Animals
-
Corpus Striatum / drug effects
-
Corpus Striatum / metabolism*
-
Dopamine / metabolism*
-
G(M1) Ganglioside / therapeutic use*
-
Homovanillic Acid / metabolism
-
Immunohistochemistry
-
Macaca fascicularis
-
Motor Activity* / drug effects
-
Parkinson Disease, Secondary / chemically induced
-
Parkinson Disease, Secondary / drug therapy*
-
Parkinson Disease, Secondary / metabolism
-
Putamen / drug effects
-
Putamen / metabolism
-
Reference Values
-
Saimiri
-
Tyrosine 3-Monooxygenase / metabolism
Substances
-
3,4-Dihydroxyphenylacetic Acid
-
G(M1) Ganglioside
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Tyrosine 3-Monooxygenase
-
Dopamine
-
Homovanillic Acid